Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Notice Consent Model

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Recruiting2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06781424RecruitingPrimary

University of Central Florida BEEAST

NCT06876857RecruitingPrimary

University of Central Florida CereBank

NCT02205749Not ApplicableCompletedPrimary

Preferred Consent Models for Secondary Uses of Biospecimens Among Diverse Women

Showing all 3 trials

Research Network

Common Treatments

  • Notice Consent Model1
  • Broad Consent Model1
  • Studyspecific Consent Model1

Active Sponsors

  • University of Central Florida2
  • Washington University School of Medicine1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Environmental Impact1
  • Brain Injury1
  • Brain Diseases1

Activity Timeline